AMEDISYS INC Quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD from Q1 2010 to Q1 2025

Taxonomy & unit: us-gaap: USD
Description: Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary: Amedisys Inc quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q1 2010 to Q1 2025.
Amedisys Inc Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending March 31, 2025 was $320M, a 11.1% decline year-over-year.

Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)

Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date	Report	Filed
Q1 2025	$320M	-$39.7M	-11.1%	Mar 31, 2025	10-Q	2025-04-24
Q4 2024	$296M	-$17.3M	-5.52%	Dec 31, 2024	10-Q	2025-04-24
Q3 2024	$301M	-$18.5M	-5.8%	Sep 30, 2024	10-Q	2024-11-07
Q2 2024	$357M	+$78.1M	+28%	Jun 30, 2024	10-Q	2024-07-25
Q1 2024	$359M	+$65.2M	+22.2%	Mar 31, 2024	10-Q	2024-04-25
Q4 2023	$313M	+$16.6M	+5.59%	Dec 31, 2023	10-K	2025-02-27
Q3 2023	$320M	+$17.1M	+5.66%	Sep 30, 2023	10-Q	2023-10-25
Q2 2023	$279M	-$26.6M	-8.72%	Jun 30, 2023	10-Q	2023-07-27
Q1 2023	$294M	+$543K	+0.19%	Mar 31, 2023	10-Q	2023-05-04
Q4 2022	$297M	+$21.8M	+7.94%	Dec 31, 2022	10-K	2024-02-22
Q3 2022	$302M	+$27.9M	+10.2%	Sep 30, 2022	10-Q	2022-10-27
Q2 2022	$305M	+$27.2M	+9.78%	Jun 30, 2022	10-Q	2022-07-28
Q1 2022	$294M	+$17.9M	+6.51%	Mar 31, 2022	10-Q	2022-04-28
Q4 2021	$275M	+$19.8M	+7.77%	Dec 31, 2021	10-K	2023-02-16
Q3 2021	$275M	+$23.8M	+9.49%	Sep 30, 2021	10-Q	2021-11-03
Q2 2021	$278M	+$29.2M	+11.7%	Jun 30, 2021	10-Q	2021-08-05
Q1 2021	$276M	+$7.08M	+2.64%	Mar 31, 2021	10-Q	2021-04-29
Q4 2020	$255M	+$17.5M	+7.39%	Dec 31, 2020	10-K	2022-02-24
Q3 2020	$251M	-$3.93M	-1.54%	Sep 30, 2020	10-Q	2020-10-29
Q2 2020	$249M	+$9.36M	+3.9%	Jun 30, 2020	10-Q	2020-07-29
Q1 2020	$269M	+$32.1M	+13.6%	Mar 31, 2020	10-Q	2020-05-07
Q4 2019	$238M	+$48.6M	+25.7%	Dec 31, 2019	10-K	2021-02-25
Q3 2019	$255M	+$59.7M	+30.6%	Sep 30, 2019	10-Q	2019-10-30
Q2 2019	$240M	+$42.1M	+21.3%	Jun 30, 2019	10-Q	2019-08-01
Q1 2019	$236M	+$43.5M	+22.5%	Mar 31, 2019	10-Q	2019-05-01
Q4 2018	$189M	-$12.2M	-6.08%	Dec 31, 2018	10-K	2020-02-19
Q3 2018	$195M	+$17.6M	+9.94%	Sep 30, 2018	10-Q	2018-10-30
Q2 2018	$198M	+$24.2M	+14%	Jun 30, 2018	10-Q	2018-08-01
Q1 2018	$193M	+$20.2M	+11.7%	Mar 31, 2018	10-Q	2018-05-08
Q4 2017	$201M	+$35.1M	+21.2%	Dec 31, 2017	10-K	2019-02-28
Q3 2017	$177M	+$14.9M	+9.17%	Sep 30, 2017	10-Q	2017-11-08
Q2 2017	$173M	+$21.2M	+13.9%	Jun 30, 2017	10-Q	2017-07-27
Q1 2017	$173M	+$18.8M	+12.2%	Mar 31, 2017	10-Q	2017-05-03
Q4 2016	$166M	+$41M	+32.8%	Dec 31, 2016	10-K	2018-02-28
Q3 2016	$163M	+$40.8M	+33.5%	Sep 30, 2016	10-Q	2016-11-04
Q2 2016	$152M	+$41.8M	+37.8%	Jun 30, 2016	10-Q	2016-08-03
Q1 2016	$154M	+$43.2M	+39.1%	Mar 31, 2016	10-Q	2016-05-04
Q4 2015	$125M	+$25.7M	+25.9%	Dec 31, 2015	10-K	2017-03-01
Q3 2015	$122M	+$18.9M	+18.4%	Sep 30, 2015	10-Q	2015-11-05
Q2 2015	$110M	-$480K	-0.43%	Jun 30, 2015	10-Q	2015-07-29
Q1 2015	$111M	-$4.7M	-4.07%	Mar 31, 2015	10-Q	2015-04-29
Q4 2014	$99.3M	-$11.8M	-10.6%	Dec 31, 2014	10-K	2016-03-10
Q3 2014	$103M	-$8.29M	-7.46%	Sep 30, 2014	10-Q	2014-10-29
Q2 2014	$111M	-$13.8M	-11.1%	Jun 30, 2014	10-Q	2014-07-30
Q1 2014	$115M	-$29.3M	-20.3%	Mar 31, 2014	10-Q	2014-05-08
Q4 2013	$111M	-$58M	-34.3%	Dec 31, 2013	10-K	2015-03-04
Q3 2013	$111M	-$52.3M	-32%	Sep 30, 2013	10-Q	2013-11-12
Q2 2013	$125M	-$38.4M	-23.5%	Jun 30, 2013	10-Q	2013-07-31
Q1 2013	$145M	-$17.2M	-10.6%	Mar 31, 2013	10-Q	2013-04-30
Q4 2012	$169M	+$21.1M	+14.3%	Dec 31, 2012	10-K	2014-03-12

Previous1 2Next

Showing 1 to 50 of 61 entries

* An asterisk sign (*) next to the value indicates that the value is likely invalid.